Qlucore announces 3 year license from Europe's largest biopharmaceutical company
LUND, SWEDEN - Jul 15, 2015 - ~~Qlucore announces 3 year license
from Europe's largest biopharmaceutical company
Software to help Actelion visualize and analyze big data
Qlucore, a world leader in the development of bioinformatics
software, has announced a three year license contract with
Actelion, one of Europes leading biopharmaceutical
companies.
Actelion is a leader in the science and medicine of pulmonary
arterial hypertension (PAH), and its understanding of the complex
pathways and molecular mechanisms of this disease has enabled the
development of tailored medicines that can make a real difference
to patient outcomes. With over 15 years of experience, Actelions
Drug Discovery group, based in Allschwil, Switzerland combines
state-of-the-art technology with human expertise and teamwork.
Scientists use an inquisitive drug hunting approach to discover and
develop novel medicines to improve patients' lives. Actelion has
over 100 medicinal and process chemists creating low molecular
weight compounds which go through a cyclical drug discovery process
for optimization. These innovative compounds are then characterized
by molecular biologists and biochemists in relation to the chosen
molecular drug targets.
Actelion has been using Qlucore Omics Explorer for exploration and
analysis of large data sets, mainly within Translation Science,
since 2011. One of the most pressing challenges facing scientists
today is whats known as big data - complex datasets that have
grown so large that they become nearly impossible to analyse using
traditional tools.
We are delighted that Actelion is making this long-term commitment
to Qlucore with the multi-year license. commented Carl-Johan
Ivarsson, President of Qlucore This shows the confidence that
Actelion has in our product and is an endorsement of not only of
our software but the working relationship between our two
companies.
For scientists and researchers the benefits of working with larger
and larger data sets allows them to spot trends and ultimately help
in the fight against human disease. However, faced with such large
volumes of data, it is often very difficult - if not impossible -
for scientists to derive any real biological meaning from their
findings with the naked eye alone and researchers face big problems
and delays trying to analyze the sheer quantity of data.
Qlucore Omics Explorer features the latest data visualisation
techniques and presentation technologies which is making it much
easier for researchers to examine enormous quantities of data, to
test different hypothesis much more quickly, and to explore
alternative scenarios within seconds, all without having to rely
exclusively on the help of specialist bioinformaticians and
biostatisticians.
Biologists within Actelions research organizations have become
more active in data analysis and exploration by using Qlucore Omics
Explorer. Actelion plans to increase its use of Qlucores software,
extending to more research teams by placing this 3 years license
order.
~~www.qlucore.com